New York, Feb 4, 2026, 16:41 EST — After-hours
- Shares of Boston Scientific tumbled roughly 18% after the company reported weaker-than-expected electrophysiology sales.
- Investors zeroed in on weaker U.S. demand for Watchman and a dimmer growth forecast for 2026.
- Traders are gearing up for Thursday, eyeing analyst revisions and any new insights on heart-rhythm procedure trends.
Shares of Boston Scientific plunged Wednesday following a disappointing sales report from its electrophysiology division, a key growth driver closely watched by investors. The stock dropped $16.23, or roughly 17.7%, to $75.50 in after-hours trading.
This shift is significant because it targets two key franchises fueling the bull case: electrophysiology tools for minimally invasive heart-rhythm procedures, and Watchman, the stroke-prevention implant designed for atrial fibrillation patients.
“This was not the quarter that was hoped for,” J.P. Morgan analyst Robbie Marcus said, highlighting shortfalls in U.S. electrophysiology and Watchman sales. He cautioned that the focus will return to whether those growth trends can hold up. MedTech Dive
Boston Scientific didn’t ease concerns with its forecast. The company expects first-quarter adjusted earnings per share between $0.78 and $0.80, alongside organic revenue growth of 8.5% to 10%. Organic growth excludes currency fluctuations and some acquisition impacts.
The softer near-term tone cast a shadow over a quarter that otherwise met Wall Street’s expectations on headline revenue and profit, while also delivering a slew of pipeline and commercial updates.
Several Street analysts suggested the selloff might have gone too far. RBC Capital Markets stuck with an “Outperform” rating and a $130 price target, viewing the dip as a buying opportunity despite the weak near-term guidance. Barron’s
Electrophysiology has become a fiercely contested arena. Boston Scientific’s Farapulse platform goes head-to-head in pulsed-field ablation—a rapidly expanding segment of heart-rhythm treatment—with offerings from bigger players like Johnson & Johnson and Medtronic.
The risk remains clear: if the Q4 electrophysiology miss signals weaker U.S. adoption or pricing pressure instead of just timing issues, we could see estimates cut again and the multiple tighten further. Watchman is another key variable; any prolonged weakness in U.S. demand would hit hard, given its reputation as a more reliable growth driver.
Boston Scientific’s investor calendar is sparse for now. No events are on the docket, so the next trigger will be the upcoming quarterly results and any fresh analysis from the sell side.
Traders are eyeing Thursday’s open for any downgrades, target cuts, or revisions linked to electrophysiology and Watchman assumptions. The key question: can management convince investors this quarter was just a blip, not the start of a trend?
